conferenceseries.com

2nd International Conference on

Hepatology

May 09-11, 2016 Chicago, USA

The effects of 4-nonylphenol administration induced oxidative damages in liver and contributes to hepatic steatosis in male rats

Ansoumane Kourouma

Huazhong University of Science and Technology, P. R. China

An emerging literature suggests that early life exposure to 4-nonylphenol (4-NP), a widespread endocrine disrupting chemical, may increase the risk of metabolic syndrome. In this study, we investigated the hypothesis that intraperitoneal administration of 4-NP induce hepatic steatosis in rat. 24 males Sprague-Dawley rats were administered with 4-NP (0, 2, 10 and 50 mg/kg b.wt) in corn oil during 30 days. Liver histology, biochemical analysis and gene expression profiling were examined. After treatment, abnormal liver morphology and function were observed in the 4-NP-treated rat, and significant changes in gene expression as indicator of hepatic steatosis and apoptosis were observed compared with controls. Up-regulated genes involved in apoptosis, Hepatotoxity and OS, increased ROS and decrease of antioxidant enzyme were observed in the 4-NP exposed rat. Extensive fatty accumulation in liver section and elevated serum SGOT, SGPT, LDH and γ -GT were also observed. Incidence and severity of liver steatosis was scored and taken in to consideration (steatosis, ballooning and lobular inflammation). Hepatocyte apoptosis could promote NAFLD progression; Fas/FasL, TNF- α and Caspase-9 mRNA activation were important contributing factors to hepatic steatosis. These findings provide the first evidence that 4-NP affects the gene expression related to liver hepatotoxicity, which is correlated with hepatic steatosis.

kourouma_00@yahoo.fr

CCL18/PITPNM3 enhances migration, invasion, and EMT through the NF-кВ signaling pathway in hepatocellular carcinoma

Wenbin Li, Zeyu Lin and **Jie Wang** Sun Yat-Sen University, China

Chemokine ligand 18 (CCL18) has been associated with hepatocellular carcinoma (HCC) metastasis. Here, we demonstrated a novel mechanism through which CCL18 enhances cell migration, invasion, and epithelial-mesenchymal transition (EMT) in HCC. (1) Using immunohistochemistry, we analyzed the expression of PITPNM3, a molecule that correlated with CCL18 signaling, in 149 HCC tissue specimens. The results showed that PITPNM3 expression is highly associated with tumor metastasis and differentiation; (2)in vitro experiments showed that CCL18 enhances cell migration, invasion, and EMT in PITPNM3 (+) HCC cells but not in PITPNM3(-) cells. Silencing of PITPNM3 by short interfering RNA (siRNA) inhibited the induction of cell migration, invasion, and EMT by CCL18; (3) Cell migration, invasion, and EMT induced by CCL18 accompanied with the phosphorylation of IKK and IKBa as well as p65 nuclear translocation in PITPNM3(+) HCC cells, but not in the cells that PITPNM3 is silenced with siRNA, implying that the activation of NF- κ B signaling is involved in the action of CCL18/PITPNM3. These results suggest that CCL18 enhances HCC cell migration, invasion, and EMT through the expression of PITPNM3 and the activation of the NF- κ B signaling pathway.

gzsurgeon@hotmail.com